Sanofi and Regeneron Pharmaceuticals, the duo behind the hugely successful drug Dupixent, are re-upping their partnership, with the companies announcing Thursday an expanded collaboration on a new series of antibodies for immunological diseases.
As part of the pact, Sanofi is paying Regeneron $1 billion upfront, with possible milestone payments of up to $7 billion more. The deal involves Regeneron taking the lead on research and development, with Sanofi spearheading commercial efforts. Profits on the medicines would be split evenly.
“By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology,” George Yancopoulos, Regeneron’s chief scientific officer, said in a statement.
